![\"SCMP_C-Suite](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/09\/8176eb56-260f-4c9b-b301-5e8df47a52ef_692f6a9a.jpg\" "\\"SCMP_C-Suite")
SCMP_C-Suite The Game Changers_Roche Diagnostics_Changing The Game<\/p>\nSCMP_C-Suite The Game Changers_Roche Diagnostics_Changing The Game<\/p>\n
\u201cMoving from the reactive acute-treatment base into a more proactive base healthcare system is always our wish,\u201d Lo says. \u201cEarly diagnosis is always important.\u201d<\/p>\n
The consequences of late detection, he argues, extend far beyond financial strain. By the time many conditions are diagnosed at advanced stages, progression may be irreversible. The cost is borne not only by hospital budgets but by patients and families confronting pain, anxiety and diminished quality of life.<\/p>\n
\u201cThe value of diagnostics is not only just to do the test,\u201d Lo says. \u201cIt is also linked to the health and economy system.\u201d<\/p>\n
He points to heart failure, where earlier cardiomarker testing can allow patients to leave hospital sooner, easing bed shortages and lowering costs. In oncology, earlier molecular testing can guide targeted therapies and avoid ineffective treatments. In diabetes \u2013 one of Hong Kong\u2019s heaviest healthcare burdens \u2013 timely HbA1c testing can alter the long-term trajectory of disease.<\/p>\n
Sometimes, he notes, prevention means avoiding treatment altogether. \u201cSometimes it\u2019s not necessary to have a treatment,\u201d he says. \u201cIt could mean just changing their lifestyle a little bit.\u201d<\/p>\n
Covid-19 was a turning point. The pandemic placed extraordinary strain on healthcare systems, but it also elevated public awareness of diagnostics. Roche supplied the first batch of molecular Covid-19 testing reagents to Hong Kong\u2019s Hospital Authority, an experience Lo describes as both demanding and deeply meaningful.<\/p>\n
\u201cCovid itself was really a healthcare challenge to the system,\u201d he says, \u201cto test out the overarching healthcare resilience.\u201d<\/p>\n
The crisis also demystified laboratory science. \u201cBefore this, no one knew what a PCR was,\u201d Lo recalls with a smile. \u201cBut now everyone knows.\u201d<\/p>\n
That shift in understanding has opened the door to broader conversations about how diagnostics can shape healthcare beyond emergencies.<\/p>\n
Shaping Tomorrow![\"SCMP_C-Suite](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/09\/e37306fe-553b-4354-8680-690f5e1ca120_692f6a9a.jpg\" "\\"SCMP_C-Suite")
SCMP_C-Suite The Game Changers_Roche Diagnostics_Shaping Tomorrow<\/p>\n
Lo believes Hong Kong\u2019s policy direction is increasingly aligned with prevention. He cites the government\u2019s Primary Healthcare Blueprint and Chronic Disease Co-Care Programme as evidence of a growing recognition that early screening and community-based care are essential to sustainability.<\/p>\n
\u201cThe direction has turned from the reactive to the proactive to a more prevention-based healthcare system,\u201d he says.<\/p>\n
Technology is accelerating that shift. In today\u2019s advanced laboratories, Roche can integrate multiple chemistry, immunology and molecular diagnostics platforms into one automated system, and each platform can process up to 6,400 tests an hour. Robotics now transport and load blood samples with minimal human handling, to reduce errors and turnaround time.<\/p>\n
Mass spectrometry, once considered highly specialised, has been introduced into routine workflows in Hong Kong, capable of analysing molecular markers at speeds that would have been unimaginable earlier in Lo\u2019s career.<\/p>\n
Yet he insists that machines alone are not transformative. \u201cDigital and data will be extremely important,\u201d he says. \u201cNow data is equal to cash and equal to the brain.\u201d<\/p>\n
Artificial intelligence (AI) is layered onto traditional biomarkers to enhance predictive power. In liver cancer screening, combining classic tests with additional markers and digital algorithms can significantly increase the ability to identify patients at highest risk.<\/p>\n
Lo\u2019s vision extends beyond the laboratory walls. He describes a value chain shifting \u201cfrom hospital to home\u2026 to home prevention\u201d.<\/p>\n
One example is Roche\u2019s AI-enabled continuous glucose monitoring system for diabetes patients. A person living with diabetes may make hundreds of daily decisions related to blood sugar management. With AI support, the system can anticipate dangerous lows and prompt preventive action before symptoms occur.<\/p>\n
\u201cIf you can have this AI-enabled system to help them, that really can change their life,\u201d he says.<\/p>\n
He sees informed patients as a strength rather than a challenge. In an era when people routinely search their test results online or consult AI tools, Lo believes empowerment can drive better engagement.<\/p>\n
\u201cThe more knowledgeable people are, the more they will have the ability to care for themselves,\u201d he says.<\/p>\n
Lessons That Last![\"SCMP_C-Suite](\"https:\/\/www.europesays.com\/ch\/wp-content\/uploads\/2026\/09\/8561c7db-541f-4656-b830-6d30a4ee121a_692f6a9a.jpg\" "\\"SCMP_C-Suite")
SCMP_C-Suite The Game Changers_Roche Diagnostics_Lessons That Last<\/p>\n
Despite overseeing advanced technologies, Lo\u2019s leadership philosophy is deliberately simple.<\/p>\n
\u201cHow you lead yourself demonstrates how you lead your team,\u201d he says. \u201cAnd this shows how you would lead the wider organisation.\u201d<\/p>\n
His own career began as a medical laboratory technologist before expanding into regional roles across Asia, including a transformative stint in South Korea during the pandemic. Titles matter less, he says, than purpose and humility.<\/p>\n
\u201cIf you do the right things at the right time for the right segment or right person, then the revenue will come,\u201d he says.<\/p>\n
His urgency remains anchored in human experience. He recalls struggling to draw blood from a cancer patient whose veins had been damaged by chemotherapy.<\/p>\n
\u201cAll that patient wanted was to have a few months more to live,\u201d Lo says quietly. \u201cThat\u2019s why time matters.\u201d<\/p>\n
Innovation, he acknowledges, requires investment, regulatory alignment and proof of economic value. But speed matters. Delayed adoption means delayed benefit for patients who may not have the luxury of waiting.<\/p>\n
\u201cNo matter how wonderful innovation is, if you cannot bring it through the right access to the patient, there is nothing,\u201d he says.<\/p>\n
Asked how he hopes to be remembered, Lo does not speak of market leadership or technological milestones. He hopes simply to be seen as one of the contributors who helped move healthcare closer to prevention.<\/p>\n
\u201cI really love IVD,\u201d he says, referring to in vitro diagnostics. \u201cThat\u2019s it.\u201d<\/p>\n
In a city where hospitals have long been the focal point of care, Ronald Lo is arguing that the future lies elsewhere \u2013 in earlier tests, smarter data, connected systems and empowered patients who never need to be admitted at all.<\/p>\n","protected":false},"excerpt":{"rendered":"SCMP_C-Suite The Game Changers_Roche Diagnostics_Changing The Game \u201cMoving from the reactive acute-treatment base into a more proactive base…\n","protected":false},"author":2,"featured_media":126716,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[2252,225,61859,14585,3260,61857,61861,14458,9065,134,61860,61858,1220],"class_list":["post-126715","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-ai","tag-artificial-intelligence","tag-chronic-disease-co-care-programme","tag-covid-19","tag-hong-kong","tag-hospital-authority","tag-ivd","tag-pcr","tag-primary-healthcare-blueprint","tag-roche","tag-roche-diagnostics-hong-kong","tag-ronald-lo","tag-south-korea"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117226254449559184","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=126715"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/126715\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/126716"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=126715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=126715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=126715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}